Patients, Data Source, and Inclusion Criteria

The national CORECT registry was used as a data source for the present analysis. The CORECT registry was a post-marketing database gathering anonymized data of CRC patients treated with targeted agents in the Czech Republic containing data on baseline characteristics, course of treatment, and outcomes.

The data entries were updated twice a year. The therapy with targeted agents in the Czech Republic outside of clinical trials is reimbursed only in comprehensive cancer centers, and the registry has been estimated to provide data on approximately 95% of all patients treated with targeted therapy for mCRC in these centers.⁸ There are 17 comprehensive cancer centers and all have contributed to the database. The contribution to the patient-based database was mandatory for regorafenib reimbursed by public health insurance.⁷ There was no external monitoring of the data. The cohort for analysis included all patients with colorectal adenocarcinoma and valid data in the registry (including baseline patient characteristics, treatment, and follow-up data) who received regorafenib from 2011 to 2017. The data cut-off was October 2, 2017.